- Home
- ALDF vs ABEO Comparison
ALDF vs ABEO Comparison
Compare ALDF & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDF
- ABEO
- Stock Information
- Founded
- ALDF 2024
- ABEO N/A
- Country
- ALDF United States
- ABEO United States
- Employees
- ALDF N/A
- ABEO N/A
- Industry
- ALDF
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- ALDF
- ABEO Health Care
- Exchange
- ALDF NYSE
- ABEO Nasdaq
- Market Cap
- ALDF 296.6M
- ABEO 253.0M
- IPO Year
- ALDF 2024
- ABEO 1980
- Fundamental
- Price
- ALDF $10.03
- ABEO $5.78
- Analyst Decision
- ALDF
- ABEO Strong Buy
- Analyst Count
- ALDF 0
- ABEO 4
- Target Price
- ALDF N/A
- ABEO $17.25
- AVG Volume (30 Days)
- ALDF 2.1K
- ABEO 277.4K
- Earning Date
- ALDF 01-01-0001
- ABEO 03-17-2025
- Dividend Yield
- ALDF N/A
- ABEO N/A
- EPS Growth
- ALDF N/A
- ABEO N/A
- EPS
- ALDF N/A
- ABEO N/A
- Revenue
- ALDF N/A
- ABEO N/A
- Revenue This Year
- ALDF N/A
- ABEO N/A
- Revenue Next Year
- ALDF N/A
- ABEO $15,721.96
- P/E Ratio
- ALDF $79.36
- ABEO N/A
- Revenue Growth
- ALDF N/A
- ABEO 147.52
- 52 Week Low
- ALDF $9.98
- ABEO $3.05
- 52 Week High
- ALDF $11.46
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- ALDF N/A
- ABEO 52.03
- Support Level
- ALDF N/A
- ABEO $5.79
- Resistance Level
- ALDF N/A
- ABEO $6.16
- Average True Range (ATR)
- ALDF 0.00
- ABEO 0.23
- MACD
- ALDF 0.00
- ABEO 0.02
- Stochastic Oscillator
- ALDF 0.00
- ABEO 50.00
About ALDF ALDEL FINL II INC
Aldel Financial II Inc is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.